Abstract
Background Risk stratification is a cornerstone of the Pediatric Infectious Diseases Society COVID-19 treatment guidance. This systematic review and meta-analysis aimed to define the clinical characteristics and comorbidities associated with critical COVID-19 in children and adolescents.
Methods Two independent reviewers screened the literature (Medline and EMBASE) for studies published through August 2023 that reported outcome data on patients aged ≤21 years with COVID-19. Critical disease was defined as an invasive mechanical ventilation requirement, intensive care unit admission, or death. Random effects models were used to estimate pooled odds ratios (OR) with 95% confidence intervals (CI), and heterogeneity was explored through subgroup analyses.
Results Among 10,178 articles, 136 studies met the inclusion criteria for review. Data from 70 studies, which collectively examined 172,165 children and adolescents with COVID-19, were pooled for meta-analysis. In previously healthy children, the absolute risk of critical disease from COVID-19 was 4% (95% CI, 1%–10%). Compared with no comorbidities, the pooled OR for critical disease was 3.95 (95% CI, 2.78–5.63) for presence of one comorbidity and 9.51 (95% CI, 5.62–16.06) for ≥2 comorbidities. Key risk factors included cardiovascular and neurological disorders, chronic pulmonary conditions (excluding asthma), diabetes, obesity, and immunocompromise, all with statistically significant ORs >2.00.
Conclusions While the absolute risk for critical COVID-19 in children and adolescents without underlying health conditions is relatively low, the presence of one or more comorbidities was associated with markedly increased risk. These findings support the importance of risk stratification in tailoring pediatric COVID-19 management.
Summary This systematic review with meta-analysis integrated data from 136 studies (172,165 patients) and identified diabetes; obesity; immunocompromise; and cardiovascular, neurological, and pulmonary disease as predictors of severe pediatric COVID-19. The presence of multiple comorbidities increases the risk of critical outcomes.
Competing Interest Statement
C.R.O. receives grant support from the National Institutes of Health, grant numbers OT2HL161847, K23AI159518 and R01AI123204. G.M.M. receives research support from Astellas and SymBio Pharma. P.K.S. has received support to his institution from Gilead Sciences Inc., Merck Inc. and Allovir Inc. for participation in sponsored research. Z.I.W. has received support to his institution from Pfizer and Merck for participation in sponsored research. S.H.J has received support to his institution from Gilead for participation in sponsored research and has been a consultant for Bayer, outside the scope of this work.
Funding Statement
This work was supported, in part, by the National Institutes of Health grant number K23AI159518 (Oliveira). Contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
